This guide explains what cagrilintide is, the signs it may help, how the amylin pathway works, who is a candidate, the benefits and the real side effects, how it compares with GLP-1 medications, and what treatment involves
10.1016/j.physbeh.2014.12.044 Physiol Behav
Vildagliptin was found to reduce fasting glucose, 4-h prandial glucose excursion and mean 24-hr glucose by 1 mmol/l and HbA1c by 0.4% (5 mmol/mol) after 4 weeks
These patches do not contain GLP-1 medications like semaglutide or tirzepatide, and there are no clinical trials showing GLP1like outcomes
Policy The findings support continuing the use of GLP-1 medications in women with metabolic risk factors who are considering pregnancy, says Cara Dolin, MD, a maternal-fetal medicine specialist, and a coauthor of the research, which was presented at the Society of Maternal-Fetal Medicine pregnancy meeting in February 2026